TOP TEN perturbations for 38968_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38968_at
Selected probe(set): 201811_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38968_at (201811_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):5.42395Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):4.648713Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):4.4820614Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.413328Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (hyperdiploid)
Relative Expression (log2-ratio):-4.322131Number of Samples:6 / 17
| Experimental | precursor-B-ALL study 3 (PAX5-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (hyperdiploid) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Relative Expression (log2-ratio):4.2056274Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) |
| CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
precursor-B-ALL study 2 (MLL-rearranged) / precursor-B-ALL study 2 (hyperdiploid)
Relative Expression (log2-ratio):-4.1966286Number of Samples:4 / 27
| Experimental | precursor-B-ALL study 2 (MLL-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
| Control | precursor-B-ALL study 2 (hyperdiploid) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG). |
precursor-B-ALL study 3 (E2A-PBX1) / precursor-B-ALL study 3 (hyperdiploid)
Relative Expression (log2-ratio):-4.0089884Number of Samples:6 / 17
| Experimental | precursor-B-ALL study 3 (E2A-PBX1) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (hyperdiploid) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):3.87782Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA cycT1) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | cycT1 depletion study 2 (shRNA) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
precursor-B-ALL study 3 (PAX5-rearranged) / precursor-B-ALL study 3 (BCR-ABL)
Relative Expression (log2-ratio):-3.8247728Number of Samples:6 / 4
| Experimental | precursor-B-ALL study 3 (PAX5-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (BCR-ABL) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |